Stoke Therapeutics Receives FDA Approval to Administer Higher Single Dose of STK-001 in MONARCH Trial for Dravet Syndrome
Stoke Therapeutics' experimental therapy for Dravet syndrome is being tested in the U.S.-based Phase 1/2a MONARCH trial, where a higher single dose of STK-001 will be administered. The U.S. Food and D ...